Press Releases April 27, 2026 04:25 PM

Beta Bionics to Present at the Bank of America Securities Health Care Conference

Beta Bionics to Present at Bank of America Securities Health Care Conference

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
BBNX

Beta Bionics, Inc., a Nasdaq-listed medical device company specializing in advanced diabetes management solutions, announced its management will present at the upcoming Bank of America Securities Health Care Conference. The company is known for its iLet Bionic Pancreas, an FDA-cleared autonomous insulin delivery system.

Beta Bionics to Present at the Bank of America Securities Health Care Conference
BBNX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Beta Bionics is presenting at a major healthcare securities conference, increasing visibility among investors.
  • The company focuses on advanced adaptive closed-loop algorithms for diabetes management, highlighting innovation in medical devices.
  • The iLet Bionic Pancreas is FDA-cleared and commercial-stage, signaling progress in improving diabetes treatment.

IRVINE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at the Bank of America Securities Health Care Conference in Las Vegas on Tuesday, May 12, 2026 at 2:20 pm Eastern Time (11:20 am Pacific Time).

A live audio webcast of the presentation will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com, and will be archived there for future replay following the event.

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.

Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com

Media and Public Relations:
Felicia Sanborn
Vice President of Marketing
media@betabionics.com

Source: Beta Bionics, Inc.


Risks

  • Market adoption and sales success of the iLet Bionic Pancreas remain uncertain in a competitive medical device sector.
  • Regulatory and reimbursement changes could impact future commercialization efforts.
  • Technological reliability and user acceptance of autonomous insulin delivery systems entail ongoing challenges.

More from Press Releases

Willis appoints Trevor Madden as Head of Captive and Insurance Management Solutions, Asia Pacific Sep 6, 2026 Zhihu Inc. Announces Proposed Subscription in AI-Focused Investment Fund Sep 6, 2026 Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call Sep 6, 2026 Verizon Waives Charges for Hurricane Lowell, Prepares Network in Hawai'i Sep 5, 2026 Royalty Pharma announces update on Novartis’ Phase 3 topline results for pelacarsen Sep 4, 2026